Talquetamab Plus Daratumumab and Pomalidomide and Talquetamab Plus Daratumumab Prolong PFS Among Previously Treated Patients with Relapsed Or Refractory Multiple Myeloma By Ogkologos - July 2, 2026 114 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MonumenTAL-3 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Man Walks Entire Continent To Spread Awareness About Mental Health &... January 16, 2022 A Combination of Trastuzumab with Gemcitabine and Cisplatin Shows Promising Activity... November 24, 2023 Clinical Trials in Molecular Testing for Early-Stage Lung Cancer: IMpower010, ADAURA,... June 15, 2022 What to Know About Coping With Breast Cancer During Pregnancy: An... November 14, 2023 Load more HOT NEWS Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced... How to Talk About Advanced Cancer Care Planning: An Expert Discussion Woman, 88, Had Been Waving from Her Window for Over a... Results of Pivotal Study with BCMA Specific CAR T-Cell Therapy in...
